<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393975</url>
  </required_header>
  <id_info>
    <org_study_id>281102</org_study_id>
    <nct_id>NCT03393975</nct_id>
  </id_info>
  <brief_title>A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13)</brief_title>
  <official_title>A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2-period Crossover Study With a Single Arm Continuation Evaluating the Safety and Efficacy of BAX 930 (rADAMTS13) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To purpose of this study is to assess safety and efficacy of BAX 930 in the prevention and
      treatment of acute episodes of thrombotic thrombocytopenic purpura (TTP) in subjects with
      severe hereditary deficiency of ADAMTS13 (cTTP; defined as plasma ADAMTS13 &lt;10%, as measured
      by the fluorescent resonance energy transfer-VWF73 [FRETS] assay)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">January 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a Phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute thrombotic thrombocytopenic purpura (TTP) episodes</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Incidence of acute TTP episodes among participants receiving either BAX 930 or standard of care (SoC) prophylactically</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of acute thrombotic thrombocytopenic purpura (TTP) episodes responding to BAX 930</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Defined as not requiring the use of another ADAMTS13-containing agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute thrombotic thrombocytopenic purpura (TTP) episodes responding to BAX 930</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Defined as not requiring the use of another ADAMTS13-containing agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of clinical symptomatology</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Time to resolution of clinical symptomatology, if present, and normalization of laboratory parameters following initiation of treatment in acute thrombotic thrombocytopenic purpura (TTP) episodes with BAX 930 or standard of care (SoC) agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thrombocytopenia</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Defined as a drop in platelet count ≥25% of baseline or a platelet count &lt;150,000/μL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of microangiopathic hemolytic anemia</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Defined as an elevation of lactate dehydrogenase (LDH) &gt;1.5× upper limit of normal (ULN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neurological symptoms</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Incidence of neurological symptoms (e.g., confusion, dysphonia, dysarthria, focal or general motor symptoms including seizures)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of renal dysfunction</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>defined as an increase in serum creatinine &gt;1.5×baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abdominal pain</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Incidence of abdominal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of supplemental doses</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Incidence of supplemental doses prompted by subacute manifestations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose modification</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Incidence of dose modification not prompted by an acute event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute thrombotic thrombocytopenic purpura (TTP) episodes</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Incidence of acute TTP episodes while subjects are on their final dose and dosing regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Incidence of product-related and unrelated AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibodies to ADAMTS13</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Incidence of binding and inhibitory antibodies to ADAMTS13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant changes in vital signs</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Clinically relevant changes in vital signs includes: body temperature, pulse rate, respiratory rate, and blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant changes in clinical chemistry</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Clinically relevant changes in clinical chemistry includes: sodium, potassium, chloride, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, and glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant changes in hematology</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>Clinically relevant changes in hematology includes: red blood cell (RBC) count, hemoglobin, hematocrit, haptoglobin, reticulocyte count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), leukocytes (i.e., white blood cell count) with differential (i.e., basophils, eosinophils, lymphocytes, monocytes, and neutrophils) and platelet counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated total quantity of ADAMTS13 administered</measure>
    <time_frame>Throughout the study period of approximately 26 months. Acute events typically require 3-4 days of intensified treatment.</time_frame>
    <description>Estimated total quantity of ADAMTS13 administered during the treatment of acute events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Incremental Recovery (IR)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>For both the SoC agent and BAX 930</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: area under the plasma curve [AUC]</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>For both the SoC agent and BAX 930</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Half Life (T-1/2)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>For both the SoC agent and BAX 930</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: mean residence time (MRT)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>For both the SoC agent and BAX 930</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Clearance (CL)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>For both the SoC agent and BAX 930</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Volume at Steady State (Vss)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>For both the SoC agent and BAX 930</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (C-max)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>For both the SoC agent and BAX 930</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of von Willebrand factor: antigen (VWF:Ag)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>Multimer pattern at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of von Willebrand factor: ristocetin cofactor activity (VWF: RCo)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>Multimer pattern at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of von Willebrand factor (VWF)</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>Multimer pattern at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ADAMTS13 activity (pre-infusion ADAMTS13 levels) and VWF parameters</measure>
    <time_frame>Start of treatment periods and end of Treatment Period 2 prophylactic cohort. &lt;12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. ≥12 years: within 60 min pre-infusion; and post-infusion at 12 timepoints up to 12 days.</time_frame>
    <description>Assessment of ADAMTS13 activity (pre-infusion ADAMTS13 levels) and VWF parameters prior to each infusion of SoC or BAX 930 and at the time of acute event presentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL): cTTP-specific patient reported outcomes (PROs)</measure>
    <time_frame>Screening visit, End of period 1 (approximately month 6), End of period 2 (approximately month 12.5), and End of period 3 (approximately month 19), or non-scheduled acute event (as needed).</time_frame>
    <description>The cTTP PRO assessment is focused on measuring the symptoms and impacts of the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL): 36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>Screening visit, End of period 1 (approximately month 6), End of period 2 (approximately month 12.5), and End of period 3 (approximately month 19), or non-scheduled acute event (as needed).</time_frame>
    <description>Self-administered, validated questionnaire. A 36-item questionnaire which measures 8 domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL): Abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)</measure>
    <time_frame>Screening visit, End of period 1 (approximately month 6), End of period 2 (approximately month 12.5), and End of period 3 (approximately month 19), or non-scheduled acute event (as needed).</time_frame>
    <description>The TSQM-9 questionnaire is a validated measure consisting of 3 domains (efficacy, convenience, and overall satisfaction) and 9 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL): EuroQol 5 Dimensions Questionnaire 3-Level (EQ-5D-3L)</measure>
    <time_frame>Screening visit, End of period 1 (approximately month 6), End of period 2 (approximately month 12.5), and End of period 3 (approximately month 19), or non-scheduled acute event (as needed).</time_frame>
    <description>This is a generic measure of health. Self-rated health is captured using a visual analog scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL): EQ-5D-youth (EQ-5D-Y)</measure>
    <time_frame>Screening visit, End of period 1 (approximately month 6), End of period 2 (approximately month 12.5), and End of period 3 (approximately month 19), or non-scheduled acute event (as needed).</time_frame>
    <description>This is a generic measure of health. Self-rated health is captured using a visual analog scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL): Pediatric Quality of Life Inventory (Ped QL)</measure>
    <time_frame>Screening visit, End of period 1 (approximately month 6), End of period 2 (approximately month 12.5), and End of period 3 (approximately month 19), or non-scheduled acute event (as needed).</time_frame>
    <description>The Ped QL is a generic HRQoL instrument designed specifically for a pediatric population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization: hospital length of stay for acute TTP episodes</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>This information will be gathered by the sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization: resource utilization during prophylaxis</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>This information will be gathered by the sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Utilization: days missed from school/work due to TTP-related illness</measure>
    <time_frame>Throughout the study period of approximately 26 months</time_frame>
    <description>This information will be gathered by the sites.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Congenital Thrombotic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Prophylaxis Cohort Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(1) Pharmacokinetic (PK) Assessments: PK 1 = Investigator-recommended Standard of Care (SoC) then PK 2 = BAX930. (2) Period 1 Prophylaxis (Prophy) = BAX930; Period 2 Prophy = SoC; Period 3 Prophy = BAX930. (4) PK3 = BAX930</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylaxis Cohort Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(1) Pharmacokinetic (PK) Assessments: PK 1 = BAX930 then PK 2 = Investigator-recommended Standard of Care (SoC). (2) Period 1 Prophylaxis (Prophy) = SoC; Period 2 Prophy = BAX930; Period 3 Prophy = BAX930. (4) PK3 = BAX930</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoC On-Demand Cohort (Then prophylaxis) Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(1) On-Demand Cohort = Standard of Care (SoC). (2) Period 1 Prophylaxis (Prophy) = BAX930; Period 2 Prophy = SoC; Period 3 Prophy = BAX930. (3) Pharmacokinetic (PK) Assessment = BAX930</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoC On-Demand Cohort (Then prophylaxis) Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(1) On-Demand Cohort = BAX930. (2) Period 1 Prophylaxis (Prophy) = SoC; Period 2 Prophy = BAX930; Period 3 Prophy = BAX930. (3) Pharmacokinetic (PK) Assessment = BAX930</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BAX930</intervention_name>
    <description>A recombinant human disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13</description>
    <arm_group_label>Prophylaxis Cohort Arm 1</arm_group_label>
    <arm_group_label>SoC On-Demand Cohort (Then prophylaxis) Arm 2</arm_group_label>
    <arm_group_label>SoC On-Demand Cohort (Then prophylaxis) Arm 1</arm_group_label>
    <arm_group_label>Prophylaxis Cohort Arm 2</arm_group_label>
    <other_name>BAX 930</other_name>
    <other_name>rADAMTS13</other_name>
    <other_name>recombinant ADAMTS13</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Investigator-recommended Standard of care (SoC)</description>
    <arm_group_label>Prophylaxis Cohort Arm 1</arm_group_label>
    <arm_group_label>SoC On-Demand Cohort (Then prophylaxis) Arm 2</arm_group_label>
    <arm_group_label>SoC On-Demand Cohort (Then prophylaxis) Arm 1</arm_group_label>
    <arm_group_label>Prophylaxis Cohort Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant or legally authorized representative has provided signed informed consent
             (≥18 years of age) and/or assent form (signed by legal representative if participants
             is &lt;18 years of age)

          2. Participant is 0 to 70 years of age, inclusive, at the time of screening.
             (Participants &lt;18 years of age will be enrolled only after at least 10 exposures with
             BAX 930 have been completed in at least 5 participants over 18 years of age and
             reviewed by the study medical director).

          3. Participant has a documented diagnosis of severe hereditary ADAMTS13 deficiency,
             defined as:

               -  Confirmed by molecular genetic testing, documented in participant history or at
                  screening, and

               -  A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13
                  (ADAMTS13) activity &lt;10% as measured by the fluorescent resonance energy
                  transfer- von Willebrand factor73 (FRETS-VWF73) assay, documented in participant
                  history or at screening (participants currently receiving SoC prophylactic
                  therapy may exceed 10% ADAMTS13 activity at screening) Note: Participants
                  currently receiving prophylactic therapy will be screened immediately prior to
                  their usual prophylactic infusion

          4. Participant does not display any severe thrombotic thrombocytopenic purpura (TTP)
             signs (platelet count &lt;100,000/μL and elevation of lactate dehydrogenase (LDH) &gt;2×
             upper limit of normal (ULN)) at screening. (Prophylactic cohort only).

          5. Participant is currently on a prophylactic dosing regimen or has a documented history
             of at least 1 TTP event and an ability to tolerate SoC prophylactic dosing
             (prophylactic cohort only).

          6. Participants ≥16 years of age must have a Karnofsky score ≥70% and participants &lt;16
             years of age must have a Lansky score ≥80%

          7. Participant is hepatitis C virus (HCV)-negative as confirmed by antibody or polymerase
             chain reaction testing OR HCV-positive if their disease is chronic but stable

          8. If female of childbearing potential, participant presents with a negative blood
             pregnancy test and agrees to employ adequate birth control measures for the duration
             of the study and to undergo quarterly pregnancy testing

          9. Participant is willing and able to comply with the requirements of the protocol

        Exclusion Criteria:

          1. Participant has been diagnosed with any other TTP-like disorder (microangiopathic
             hemolytic anemia), including acquired TTP

          2. Participant has known hypersensitivity to hamster proteins

          3. Participant has experienced an acute TTP episode less than 30 days prior to screening
             (prophylactic cohort only)

          4. Participant has a medical history or presence of a functional ADAMTS13 inhibitor at
             screening

          5. Participant has a medical history of genetic or acquired immune deficiency that would
             interfere with the assessment of product immunogenicity, including participants who
             are human immunodeficiency virus (HIV)-positive with an absolute cluster of
             differentiation 4 (CD4) count &lt;200/mm^3 or who are receiving chronic immunosuppressive
             drugs.

          6. Participant has been diagnosed with severe cardiovascular disease (New York Heart
             Association classes 3 to 4)

          7. Participant with end stage renal disease requiring chronic dialysis

          8. Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not
             limited to, any of the following:

               1. Serum alanine aminotransferase (ALT) ≥2×ULN

               2. International normalized ratio &gt;1.5

               3. Severe hypoalbuminemia &lt;24 g/L

               4. Portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly,
                  history of esophageal varices)

          9. In the opinion of the investigator, the participant has another clinically significant
             concomitant disease that may pose additional risks for the participant

         10. Participant has been treated with an immunomodulatory drug, excluding topical
             treatment (e.g., ointments, nasal sprays), within 30 days prior to enrollment. Use of
             corticosteroids in conjunction with administration of fresh frozen plasma (FFP) to
             prevent allergic manifestations is permitted.

         11. Participant has an acute illness (e.g., influenza, flu-like syndrome, allergic
             rhinitis/conjunctivitis, bronchial asthma) at the time of screening (prophylaxis
             cohort only)

         12. Participant is receiving or anticipates receiving another investigational drug and/or
             interventional drug within 30 days before enrollment

         13. Participant has a history of drug and/or alcohol abuse within the last 2 years

         14. Participant has a progressive fatal disease and/or life expectancy of less than 3
             months

         15. Participant is identified by the investigator as being unable or unwilling to
             cooperate with study procedures

         16. Participant suffers from a mental condition rendering him/her unable to understand the
             nature, scope, and possible consequences of the study and/or evidence of an
             uncooperative attitude

         17. Participant is a family member or employee of the sponsor or investigator

         18. If female, participant is pregnant or lactating at the time of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Ewenstein, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta now part of Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

